AI Solution for Mammography

Overcoming Challenges with Transpara

confidence, efficiency, and trust. That’s why ScreenPoint Medical developed Transpara, the most clinically validated breast AI available today. Designed to support radiologists in detecting breast cancer at the earliest possible stage, Transpara enhances both 2D and 3D mammogram interpretation. It helps improve patient outcomes by identifying up to 45% of interval cancers earlier, prioritizes exams with a high likelihood of suspicious findings, and optimizes workflow—reducing workload by up to 44% without increasing recall rates. With Transpara, you’re choosing advanced technology backed by evidence, built to improve care and streamline radiology practices.

Research That Drives Results: The Power Behind Transpara

At ScreenPoint, we believe not all research is created equal. Born from the expertise of two pioneers in image processing, our foundation is rooted in pushing the boundaries of AI for breast imaging. Through strong clinical research partnerships, we’ve built a solution that radiologists can trust. Transpara enhances workflow efficiency, delivers exceptional confidence with a 99.97% negative predictive value in unmarked studies, and addresses critical gaps in cancer detection—especially in dense breast tissue where human sensitivity can significantly decline.
Better Workflow
Whether you are reading DBT studies in a single reader screening environment like the United States, or identifying lower-risk studies for reducing reading burden in a double reading screening environment, Transpara saves practicing radiologists time – without compromising on clinical quality.
Reading faster has no value without confidence in the results. Transpara’s unmarked studies (70% of a typical screening population) have a 99.97% negative predictive value. These results save ~26% of reading time on DBT Studies (Van Winkel, et al, 2021) or up to 44% of workload in a FFDM Double-reading environment (Lång, et al, 2023)… without compromising – and sometimes improving – cancer detection rate. Save time. Save lives.
One of the barriers to confident mammography reading is breast density. Dense parenchymal tissue is known to obscure indications of cancer on screening mammograms. Human sensitivity for breast cancer on mammograms can drop from around 80% in the least dense breast tissue to between 50-60% in the densest breasts. Transpara analysis is not affected by the visual characteristics of density in the same way.

Why Transpara: Trust the Proven Breast AI

Transpara by ScreenPoint Medical isn’t just another breast AI—it’s the most clinically validated solution available, built on the pillars of confidence, workflow, and trust. Designed to support radiologists in detecting breast cancer earlier, Transpara improves patient care by identifying up to 45% of interval cancers sooner, helps prioritize high-risk mammograms, and streamlines workflow by reducing workload up to 44%—all without compromising clinical accuracy.

Evidence-Based Breast AI Performance

Confidence

Transpara’s performance has been evaluated in more than 35+ peer-reviewed studies and dozens conference presentations. All of the data on Transpara’s performance – and we have a lot of data – is public, published and readily available.

“An Artificial Intelligence–based Mammography Screening Protocol for Breast Cancer: Outcome and Radiologist Workload,” Radiology
Mammography Screening with AI (MASAI) Study; Lancet Oncology
Results on prior mammograms with a Transpara score of 10 illustrate the potential for earlier detection of breast cancers by using AI in screen-reading; “Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases”; European Radiology
Evidence-Based Breast AI Performance

work flow

Transpara Decision Support integrates seamlessly into existing workflows, helping radiologists read 2D and 3D mammograms faster and with greater confidence. Using a 10-point image-based risk scale, the Transpara Exam Score categorizes exams as Elevated, Intermediate, or Low risk—where scores 1–7 (Low Risk) have a 99.97% negative predictive value, supporting confident decision-making.

Pioneering Study Validates AI as a Safe Alternative to Double Reading in Breast Screening
The first time that a breast AI solution is featured in a randomized controlled trial, the study investigated use of AI in breast cancer screening as an alternative to double reading. With AI support, 90% of mammograms classified as “intermediate” or “low” risk and were read by only one reader while the remaining 10% labeled as “elevated” risk were read as usual by two readers.
Use of the Transpara Exam Score in a randomized controlled trial in Sweden show that Transpara-assisted workflow helps detect more cancers while safely reducing workload by up to 44% with no change in recall rate.
Improved Performance Among ALL Readers

Trust

Transpara is FDA cleared and CE Marked and has been used to analyze more than 7 million mammograms at leading breast centers in more than 40 countries, delivering consistent results across regions and demographics. Three reader studies involving 670 mammograms and 46 radiologists from both the United States and Europe show that every radiologist, regardless of their experience level, increased their accuracy

  • Radiologists improved their breast cancer detection performance in mammograms
  • Sensitivity increases without increasing false positives
  • Radiologists do not lengthen their reading time per exam
  • Transpara stand-alone performance is comparable to radiologists

Global Partners

Transpara – The globally trusted AI solution

Lunit INSIGHT MMG successfully analyzed the mammogram of an overlooked case in 2020, where cancer was missed and the patient was diagnosed 2 years later in 2022.

0 #

In scientific papers & conference presentations

0 +

Mammograms processed

0 %

Cleared and marked 2D/FFDM and 3D/DBT. Most acquisition, most PACS integration in class

0 +

Countries worldwide (in use). Cleared for sale in 40 countries

Smarter AI for Better Breast Cancer Detection

At ScreenPoint Medical, we’re revolutionizing breast cancer screening with cutting-edge deep learning technology backed by strong clinical evidence. Since our founding in 2014 by renowned experts Professor Nico Karssemeijer and Professor Sir Michael Brady, we’ve been committed to developing AI solutions that truly make a difference. Through continuous collaboration with radiologists, our Transpara® platform is designed to improve patient outcomes by enhancing accuracy and confidence in mammography—empowering providers and giving women greater assurance in their care.

Key Benefits of Al in Mammography

  • Detecting more breast cancers

  • Rapid triage of normal cases

  • Improving reading performance of general radiolog

  • Supporting decision-making on BI-RADS 3 and

Product Enquiry